Tyruko Evropská unie - španělština - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

ACICLOVIR VIR 50 mg/g CREMA Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aciclovir vir 50 mg/g crema

industria quimica y farmaceutica vir s.a. - aciclovir - crema - 50 mg/g - aciclovir 50 mg - aciclovir

ACICLOVIR VIATRIS 50MG/G CREMA EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aciclovir viatris 50mg/g crema efg

viatris pharmaceuticals, s.l.u. - aciclovir - crema - 50 mg/g - aciclovir 50 mg - aciclovir